Fang Rongfei, Sha Chunxiu, Xie Qun, Yao Dengfu, Yao Min
Research Center of Clinical Medicine, Department of Medical Immunology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, Jiangsu Province, China.
Department of Infectious Diseases, Nantong Haian People's Hospital, Haian 226600, Jiangsu Province, China.
Anticancer Agents Med Chem. 2025;25(2):75-85. doi: 10.2174/0118715206301453240910044913.
Krüppel-like factors (KLFs, total 18 members) from the zinc finger protein (ZFP) super-family have a wide range of biological functions in hepatocellular carcinoma (HCC). This paper reviews the recent some progresses of aberrant KLFs with their potential values for diagnosis, prognosis, and targeted therapy in HCC. The recent advances of oncogenic KLFs in the diagnosis, prognosis, and targeted therapy of HCC were reviewed based on the related literature on PUBMED and clinical investigation. Based on the recent literature, KLFs, according to biological functions in HCC, are divided into 4 subgroups: promoting (KLF5, 7, 8, 13), inhibiting (KLF3, 4, 9~12, 14, 17), dual (KLF2, 6), and unknown functions (KLF1, 15, 16, or 18 ?). HCC-related KLFs regulate downstream gene transcription during hepatocyte malignant transformation, participating in cell proliferation, apoptosis, invasion, and metastasis. Some KLFs have diagnostic or prognostic value, and other KLFs with inhibiting promoting function or over-expressing inhibiting roles might be molecular targets for HCC therapy. These data have suggested that Abnormal expressions of KLFs were associated with HCC progression. Among them, some KLFs have revealed the clinical values of diagnosis or prognosis, and other KLFs with the biological functions of promotion or inhibition might be as effectively molecular targets for HCC therapy.
锌指蛋白(ZFP)超家族中的Krüppel样因子(KLFs,共18个成员)在肝细胞癌(HCC)中具有广泛的生物学功能。本文综述了异常KLFs的近期研究进展及其在HCC诊断、预后和靶向治疗中的潜在价值。基于PUBMED上的相关文献和临床研究,综述了致癌KLFs在HCC诊断、预后和靶向治疗方面的最新进展。根据近期文献,KLFs根据其在HCC中的生物学功能分为4个亚组:促进组(KLF5、7、8、13)、抑制组(KLF3、4、9~12、14、17)、双向组(KLF2、6)和功能未知组(KLF1、15、16或18?)。与HCC相关的KLFs在肝细胞恶性转化过程中调节下游基因转录,参与细胞增殖、凋亡、侵袭和转移。一些KLFs具有诊断或预后价值,而其他具有促进或抑制功能的KLFs可能是HCC治疗的分子靶点。这些数据表明KLFs的异常表达与HCC进展相关。其中,一些KLFs已显示出诊断或预后的临床价值,而其他具有促进或抑制生物学功能的KLFs可能是HCC治疗有效的分子靶点。